Illumina FY2025 EPS Forecast Increased by Leerink Partnrs

Illumina, Inc. (NASDAQ:ILMN - Free Report) - Research analysts at Leerink Partnrs lifted their FY2025 earnings per share (EPS) estimates for Illumina in a research report issued on Friday, May 9th. Leerink Partnrs analyst P. Souda now forecasts that the life sciences company will earn $4.26 per share for the year, up from their previous forecast of $4.22. The consensus estimate for Illumina's current full-year earnings is $4.51 per share. Leerink Partnrs also issued estimates for Illumina's Q1 2026 earnings at $0.90 EPS, Q2 2026 earnings at $1.03 EPS, Q3 2026 earnings at $1.17 EPS, Q4 2026 earnings at $1.44 EPS and FY2026 earnings at $4.54 EPS.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its earnings results on Thursday, May 8th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.96 by $0.01. Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. The business had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.03 billion. During the same period in the prior year, the company posted $0.98 EPS. The business's revenue for the quarter was down 1.4% compared to the same quarter last year.

Other equities analysts have also issued reports about the company. Guggenheim decreased their target price on Illumina from $122.00 to $114.00 and set a "buy" rating on the stock in a research note on Friday. Royal Bank of Canada decreased their price objective on shares of Illumina from $128.00 to $112.00 and set an "outperform" rating on the stock in a research report on Tuesday, April 8th. Canaccord Genuity Group lowered their target price on shares of Illumina from $115.00 to $92.00 and set a "hold" rating on the stock in a research note on Tuesday, April 29th. JPMorgan Chase & Co. cut their price target on shares of Illumina from $120.00 to $85.00 and set a "neutral" rating for the company in a research note on Friday. Finally, Morgan Stanley decreased their price target on shares of Illumina from $150.00 to $136.00 and set an "equal weight" rating on the stock in a report on Tuesday, February 11th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $133.00.

Illumina Trading Down 4.8%

Shares of ILMN stock opened at $75.76 on Monday. The company has a market capitalization of $11.99 billion, a PE ratio of -9.86, a price-to-earnings-growth ratio of 1.60 and a beta of 1.35. Illumina has a 52-week low of $68.70 and a 52-week high of $156.66. The business's fifty day moving average is $78.94 and its 200 day moving average is $113.12. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Golden State Wealth Management LLC bought a new stake in shares of Illumina in the 4th quarter valued at about $32,000. Fourth Dimension Wealth LLC bought a new stake in Illumina in the fourth quarter valued at approximately $40,000. Bank Julius Baer & Co. Ltd Zurich bought a new stake in Illumina in the fourth quarter valued at approximately $45,000. Assetmark Inc. boosted its stake in shares of Illumina by 954.8% during the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock valued at $44,000 after purchasing an additional 296 shares during the period. Finally, Lee Danner & Bass Inc. bought a new position in shares of Illumina in the fourth quarter worth approximately $48,000. 89.42% of the stock is owned by institutional investors.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.